Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20

Carlsmed, Inc.

Carlsmed, Inc.

CARL

0.00

Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ: CARL) with a Buy and raises the price target from $18 to $20.